American insulin nasal spray enters Phase II clinical
-
Last Update: 2020-07-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bentley Pharmaceuticals has begun a Phase II clinical trial of its human recombinant insulin nasal spray to treat post-diabetes hyperglycemiaThe Phase II Clinical Trial Evaluation Program selected 24 patients with type 1 diabetes, using randomized, single-dose four-group cross-studies to determine the dose of nasal spray equivalent to subcutaneous insulin injection and to demonstrate optimal dose efficacyThe company expects to complete Phase II clinical trials for type 1 and type 2 diabetes within the next 12 monthsThe company said two previous pilot studies in Ireland, which selected normal people and people with type 1 diabetes, showed rapid absorption of nasal spray drugs and a good blood sugar responseInsulin levels peaked in 15 to 20 minutes, the concentration increased for up to 1 hour, the peak of the drug's effect on blood sugar occurred within 40 minutes of drug use, and the efficacy decreased after 1.5 to 2 hours
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
